We revealed that none of the evaluated clinical parameters, including tumor stage and tumor grade (Figure S2A, Supplementary Table 2), or commonly used serum biomarkers—cancer antigen 125 (CA125), human epididymis protein 4 (HE4) and the risk of ovarian malignancy algorithm (ROMA) score—were significantly associated with therapy response (Figure S2B-D) across all patients, as well as within HGSOC and non-HGSOC subgroups. Here, MUC16 is linked to neoplasm.